Exec appointments at Biogen Idec and Halozyme; Succession plan for Forest Labs
US biotech firm Biogen Idec (Nasdaq: BIIB) announced that Spyros Artavanis-Tsakonas, has been named chief scientific officer. Dr Artavanis-Tsakonas had served as interim CSO while on sabbatical from Harvard Medical School.
He will now continue in this role in a permanent capacity, and will also lead the company’s research strategy, capabilities and discovery platforms. He will report to Doug Williams, executive vice president of R&D. He will continue to serve as a Professor of Cell Biology at Harvard Medical School, where he was the founding Director of the Developmental and Regenerative Biology graduate program.
David Ramsay promoted to CFO at Halozyme
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze